Ondine Biomedical Inc (OBI) NPV

- Add to watchlist
- Create an alert
- This stock can be held in a




9.25p
9.07p
13.30p
£41.00 million
9.25p
9.07p
5.13p
n/a
0.50p (5.13%) Previous:
0.50p
20,000
n/a
20,000
Performance
Not available for this stock.
Fundamental data
Year ending: | 31/12/2023 | 31/12/2022 |
---|---|---|
Revenue ($m) | 1.20 | 0.64 |
Profit before tax ($m) | (14.41) | (19.37) |
Adjusted EPS (¢): | (7.00) | (10.00) |
P/E ratio | n/a | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: US dollar
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Ondine appoints new finance, operations chief
26 February 2025 12:39
-
Ondine Biomedical gets $4m investment from HCA Healthcare subsidiary
27 January 2025 15:44
-
Ondine enrols first patient in phase three clinical trial
30 December 2024 10:02
-
Mid Yorkshire NHS Trust cuts SSI rates by 71%
2 April 2025 07:00
-
Steriwave enters ICU and related Issue of Shares
19 March 2025 07:00
-
Quebec Hospital Cuts Spine SSIs by 78%
17 March 2025 07:00
Annual & interim reports
Annual & interim reports are not available for this stock.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.